avelumab + N-803 + haNK

Avelumab + N-803 + haNK is a triple combination immunotherapy regimen under clinical investigation primarily for advanced or metastatic **Merkel cell carcinoma (MCC)** in patients who have progressed following checkpoint inhibitor therapy. - **Avelumab** is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 on T-cells and thereby enhancing antitumor T-cell immune responses. - **N-803** (also known as ALT-803) is a superagonist IL-15/IL-15 receptor alpha-Fc fusion cytokine that potently activates both NK and T-cells, promoting antitumor cytotoxicity. - **haNK** cells are an engineered allogeneic human natural killer (NK) cell line expressing a high-affinity (V158 variant) CD16 Fc gamma receptor (FcγRIIIa/CD16a), optimized for antibody-dependent cell-mediated cytotoxicity (ADCC) and endogenous IL-2 production. This combination is designed to synergistically optimize both innate (NK cell) and adaptive (T-cell) antitumor immunity: avelumab blocks immune checkpoint suppression, N-803 stimulates effector cell expansion/activation, and haNK provides enhanced antibody-dependent cellular cytotoxicity, especially when used along with avelumab[1][2][3][6][7][8].

Brand names

BavencioAnktiva

Other names

avelumab + N-803 + haNKavelumab + ALT-803 + haNKavelumab + IL-15N72D:IL-15RαSu/IgG1 Fc complex + haNK